From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
Health status
Transition Probability (annual)
From
To
Rate
Chronic hepatitis C
Compensated cirrhosis [25, 26]
0.073
Compensated cirrhosis
Decompensated cirrhosis [27, 28]
0.039
Hepatocellular carcinoma [25, 29, 30]
0.014
Decompensated cirrhosis
Hepatocellular carcinoma [25, 27, 28]
Liver transplant (1st year) [31]
0.031
Death [24, 25, 29]
0.129
Hepatocellular carcinoma
Death [25]
0.427
Liver transplant
Death (1st year) [24, 29, 32–34]
0.210
Death (> 1 year) [24, 29–32]
0.057
